-

Bayer Wins Third Consecutive Trial Victory

Company has now won 13 of last 19 cases where judgments were entered at trial

WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer won its third consecutive trial victory when a jury reached a defense verdict in its most recent trial – the Kline Roundup™ product liability trial – before Judge Ann Butchart in Philadelphia.

Separately, Plaintiffs voluntarily dismissed with prejudice the Meyer case which was at trial in the Superior Court of California for Sonoma County. These follow the defense verdict in Cody in Conway County, Arkansas, as well as a mistrial in Cloud in Delaware state court, both occurring late last week.

Bayer has now won three consecutive victories at trial, and 13 of the last 19 cases where judgments were entered at trial.

“Validating the Company’s strategy of taking cases to trial based on strong scientific and regulatory evidence, Bayer has now won three consecutive victories at trial and 13 of the last 19 cases where judgments were entered at trial,” the company said. “In these cases, the plaintiffs could not prove that Roundup™ was the cause of the injuries alleged in these cases, consistent with this science.”

The unanimous Kline verdict is the first to follow significant rulings in the Philadelphia litigation clarifying which scientific and regulatory conclusions could be admitted, a much-disputed issue in prior trials.

“While we have great sympathy for anyone who suffers a loss or injury, science proves that Roundup™ is not carcinogenic,” said the company. “We continue to stand behind the safety of Roundup™ and will confidently defend the safety of our products and our good faith actions in any future litigation.”

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Bayer


Release Versions

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Bayer

Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation

LEVERKUSEN--(BUSINESS WIRE)--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits during the Court’s 2026 session, which ends in June. “The Supreme Court decision to take the case is good news for U.S. far...

Bayer Accelerates Pharma Growth on High-Value Portfolio

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe hot flashes due to menopause. The campaign encourages women to have an open and honest conversation with their healthcare provider about their hot flash experiences and learn about treatment options, including Lynkuet® (elinzanetant) 60mg capsules, a hormone-free prescri...
Back to Newsroom